Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
130.34
+1.72 (1.34%)
At close: Nov 4, 2026, 4:00 PM EST
131.11
+0.77 (0.59%)
Pre-market: Nov 5, 2026, 7:23 AM EST
Halozyme Therapeutics Revenue
Halozyme Therapeutics had revenue of $481.00M in the quarter ending June 30, 2026, with 47.67% growth. This brings the company's total for the last twelve months to $1.66B, up 41.15% year-over-year. In the year 2025, Halozyme Therapeutics had annual revenue of $1.40B with 37.55% growth. That makes Halozyme Therapeutics the 5,612th largest company in the world by revenue and 1,425th in the United States.
Revenue (ttm)
$1.66B
Revenue Growth
+41.15%
P/S Ratio
8.89
Revenue / Employee
$3,933,187
Employees
423
Market Cap
14.79B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Halozyme Therapeutics breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.40B | 381.29M | 37.55% |
| Dec 31, 2024 | 1.02B | 186.07M | 22.44% |
| Dec 31, 2023 | 829.25M | 169.14M | 25.62% |
| Dec 31, 2022 | 660.12M | 216.81M | 48.91% |
| Dec 31, 2021 | 443.31M | 175.72M | 65.67% |
| Dec 31, 2020 | 267.59M | 71.60M | 36.53% |
| Dec 31, 2019 | 195.99M | 44.13M | 29.06% |
| Dec 31, 2018 | 151.86M | -164.75M | -52.04% |
| Dec 31, 2017 | 316.61M | 169.92M | 115.84% |
| Dec 31, 2016 | 146.69M | 11.63M | 8.61% |
| Dec 31, 2015 | 135.06M | 59.72M | 79.28% |
| Dec 31, 2014 | 75.33M | 20.54M | 37.47% |
| Dec 31, 2013 | 54.80M | 12.47M | 29.47% |
| Dec 31, 2012 | 42.33M | -13.76M | -24.54% |
| Dec 31, 2011 | 56.09M | 42.46M | 311.67% |
| Dec 31, 2010 | 13.62M | -47.19K | -0.35% |
| Dec 31, 2009 | 13.67M | 4.91M | 55.99% |
| Dec 31, 2008 | 8.76M | 4.96M | 130.66% |
| Dec 31, 2007 | 3.80M | 2.82M | 287.02% |
| Dec 31, 2006 | 981.75K | 854.54K | 671.76% |
| Dec 31, 2005 | 127.21K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Alnylam Pharmaceuticals | 5.01B |
| Jazz Pharmaceuticals | 4.72B |
| BioMarin Pharmaceutical | 3.66B |
| BioNTech SE | 2.75B |
| Exelixis | 2.50B |
| Bio-Techne | 1.22B |
| Ascendis Pharma | 1.20B |
| BridgeBio Pharma | 945.54M |
HALO News
- 2 days ago - Halozyme price target raised to $79 from $78 at JPMorgan - TheFly
- 14 days ago - Halozyme to Report Third Quarter 2026 Financial and Operating Results - PRNewsWire
- 15 days ago - Halozyme's Strong Earnings Growth Sends Shares Higher - FXEmpire
- 21 days ago - Halozyme rises 7.5% - TheFly
- 22 days ago - Halozyme price target raised to $130 from $105 at TD Cowen - TheFly
- 4 weeks ago - Halozyme price target raised to $130 from $115 at H.C. Wainwright - TheFly
- 4 weeks ago - Halozyme price target raised to $78 from $70 at JPMorgan - TheFly
- 4 weeks ago - Halozyme wins court order to block Merck's injected Keytruda in select European markets - Reuters